Search research articles
Contact Us
Filters
Showing results (101-110 of 134) with videos related to
Page
of 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
Paolo A Ascierto, David Minor, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
David S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler, Lisa Zimmer, Kevin B Kim, et al.
The Journal of Clinical Investigation
|
July 10, 2025
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade
Imran Khan, Aida Rodriguez-Brotons, Anukana Bhattacharjee, et al.
Melanoma Research
|
November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Cancer
|
December 3, 2016
Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup><sup>on-</sup><sup>V</sup><sup>600</sup> mutations in cutaneous melanoma patients
Dae Won Kim, Lauren E Haydu, Aron Y Joon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
Kevin B Kim, Richard Kefford, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma
Michael A Davies, Patricia S Fox, Nicholas E Papadopoulos, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 134) with videos related to
Sort By:
Page
of 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
Paolo A Ascierto, David Minor, Antoni Ribas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)
Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2015
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
David S Hong, Razelle Kurzrock, Jennifer J Wheler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler, Lisa Zimmer, Kevin B Kim, et al.
The Journal of Clinical Investigation
|
July 10, 2025
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockade
Imran Khan, Aida Rodriguez-Brotons, Anukana Bhattacharjee, et al.
Melanoma Research
|
November 25, 2020
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
F Stephen Hodi, Paul B Chapman, Mario Sznol, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study
Adnan Khattak, Matteo S Carlino, Tarek Meniawy, et al.
Cancer
|
December 3, 2016
Clinicopathological features and clinical outcomes associated with TP53 and BRAF<sup>N</sup><sup>on-</sup><sup>V</sup><sup>600</sup> mutations in cutaneous melanoma patients
Dae Won Kim, Lauren E Haydu, Aron Y Joon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 19, 2012
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
Kevin B Kim, Richard Kefford, Anna C Pavlick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2012
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma
Michael A Davies, Patricia S Fox, Nicholas E Papadopoulos, et al.
Page
of 14